(Q34865036)

English

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

post-traumatic stress disorder

0 references

0 references

1 reference

based on heuristic

inferred from title

0 references

biological psychiatry

1 reference

based on heuristic

inferred from title

34

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Siegfried Kasper

4

9

object named as

Siegfried Kasper

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Donatella Marazziti

object named as

Donatella Marazziti

27

0 references

Hans-Jürgen Möller

5

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

2

object named as

Joseph Zohar

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

7

object named as

Joseph Zohar

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Euripedes Constantino Miguel

28

object named as

Euripedes C Miguel

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

3

object named as

Eric Hollander

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

8

object named as

Eric Hollander

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Donald F. Klein

21

object named as

Donald F Klein

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Hans-Jürgen Möller

10

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Borwin Bandelow

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Borwin Bandelow

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Christer Allgulander

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

José Ayuso-Gutierrez

13

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

David S Baldwin

14

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Robertas Buenvicius

15

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Giovanni Cassano

16

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Naomi Fineberg

17

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Loes Gabriels

18

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Ian Hindmarch

19

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Hisanobu Kaiya

20

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Malcolm Lader

22

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Yves Lecrubier

23

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jean-Pierre Lépine

24

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Michael R Liebowitz

25

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Juan José Lopez-Ibor

26

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Kang Seob Oh

29

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Maurice Preter

30

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Rainer Rupprecht

31

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Mitsumoto Sato

32

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Vladan Starcevic

33

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Michael van Ameringen

35

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Johann Vega

36

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

248-312

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Deep brain stimulation for refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Prevention of relapse in generalized anxiety disorder by escitalopram treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cingulotomy for intractable obsessive-compulsive disorder. Prospective long-term follow-up of 18 patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pilot study of community-based cognitive behavioral group therapy for adolescents with social phobia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The high prevalence of multiple psychiatric disorders in stable outpatients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Behavioral treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluoxetine for the treatment of childhood anxiety disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Randomised controlled trial of psychological debriefing for victims of acute burn trauma.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The development of a Clinician-Administered PTSD Scale

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The efficacy of milnacipran in panic disorder: an open trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The association of alcoholism and anxiety

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Eye movement desensitization and reprocessing (EDMR) treatment for combat-related posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treatment of posttraumatic stress disorder with amitriptyline and placebo.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The relative efficacy and treatment distress of EMDR and a cognitive-behavior trauma treatment protocol in the amelioration of posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Economic costs of anxiety disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Alprazolam and diazepam in the treatment of generalized anxiety

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Psychological and pharmacological treatments of social phobia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Long-term efficacy of pregabalin in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Inositol treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Early coadministration of clonazepam with sertraline for panic disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Neuroanatomical hypothesis of panic disorder, revised

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treatment of obsessive-compulsive disorder by psychosurgery.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive behavioral group treatment for social phobia: Comparison with a credible placebo control

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A randomised controlled trial of psychological debriefing for victims of road traffic accidents

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive mediation of treatment change in social phobia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Potential effectiveness and safety of olanzapine in refractory panic disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Comparison of two treatments for traumatic stress: a community-based study of EMDR and prolonged exposure

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

An open-label trial of escitalopram in children and adolescents with social anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Prevalence and treatment of mental disorders, 1990 to 2003

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Anterior cingulotomy for refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Flawed Meta-Analyses Comparing Psychotherapy With Pharmacotherapy

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

D-cycloserine augmented exposure therapy for obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Genetics of affective and anxiety disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Anxiety as a developmental disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluoxetine in children and adolescents with OCD: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Controlled trial of exposure and response prevention in obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Risks associated with selective serotonin reuptake inhibitors in pregnancy

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS).

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Psychological treatment of panic: work in progress on outcome, active ingredients, and follow-up.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Psychological debriefing for road traffic accident victims: Three-year follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A prospective, long-term study of personality traits in patients with intractable obsessional illness treated by capsulotomy

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The role of self-directed in vivo exposure in combination with cognitive therapy, relaxation training, or therapist-assisted exposure in the treatment of panic disorder with agoraphobia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A comparison of narrative exposure therapy, supportive counseling, and psychoeducation for treating posttraumatic stress disorder in an african refugee settlement

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Diazepam and Propranolol in Panic Disorder and Agoraphobia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Memantine augmentation for refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pilot study of secondary prevention of posttraumatic stress disorder with propranolol

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A controlled comparison of eye movement desensitization and reprocessing versus exposure plus cognitive restructuring versus waiting list in the treatment of post-traumatic stress disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Memantine for treatment-resistant OCD.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Panic, suffocation false alarms, separation anxiety and endogenous opioids

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

High-dose escitalopram for the treatment of obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Sertraline treatment of panic disorder: results of a long-term study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A randomized controlled trial of individual psychological debriefing for victims of violent crime

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Quetiapine therapy for posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Can posttraumatic stress disorder be prevented with glucocorticoids?

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Low dopamine D(2) receptor binding potential in social phobia

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treatment of posttraumatic stress disorder: a review.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Psychological strategies for discontinuing benzodiazepine treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Cognitive-behavioral treatment of late-life generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Comparative efficacy, speed, and adverse effects of three PTSD treatments: Exposure therapy, EMDR, and relaxation training

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Group cognitive-behavioral treatment of panic disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Single session debriefing after psychological trauma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Suicidal ideation and suicide attempts in panic disorder and attacks.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Generalized anxiety disorder: prevalence, burden, and cost to society.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treatment of Agoraphobia With Group Exposure In Vivo and Imipramine

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Escitalopram in the treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Clinical Experience with Mirtazapine in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Neuropsychological outcome from psychosurgery for obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

The Selective GABA Reuptake Inhibitor Tiagabine for the Treatment of Generalized Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Treating Medication-Resistant Panic Disorder: Predictors and Outcome of Cognitive-Behavior Therapy in a Brazilian Public Hospital

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Fluvoxamine or Placebo in the Treatment of Panic Disorder and Relationship to Blood Concentrations of Fluvoxamine

1 reference

https://api.crossref.org/works/10.1080%2F15622970802465807

21 January 2018

Identifiers

10.1080/15622970802465807

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34865036&oldid=1798115556"